Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aurinia Pharmaceuticals Inc.

http://www.auriniapharma.com/

Latest From Aurinia Pharmaceuticals Inc.

Sanofi’s Uses Latecomer COVID Data To Highlight Bigger mRNA Strategy

The French drug maker isn’t moving its mRNA COVID-19 vaccine into Phase III, instead focusing on a GSK-partnered protein SARS-CoV-2 vaccine and applying mRNA technology elsewhere.

Vaccines Coronavirus COVID-19

Data PROpel Lynparza To Potential Prostate Cancer Megablockbuster

The Phase III PROpel study has shown that a combination of AstraZeneca's Lynparza and Johnson & Johnson's Zytiga significantly delayed disease progression as a first-line treatment for men with metastatic castration-resistant prostate cancer.

Cancer Clinical Trials

Hancock Jaffe Changes Name To enVVeno, Drops Cardiac Device To Focus On Venous Disease

The company will focus on developing its VenoValve system to treat chronic venous insufficiency and a second product for venous disease.

Clinical Trials Business Strategies

Stock Watch: How The Pandemic Impact On Pharma’s Value Chain Is Mutating

From clinical trials to in-person sales calls, the pharmaceutical value chain has been tested by the COVID-19 pandemic, but has held up. Nevertheless, recent friction within this chain may be more than a passing irritation.

Distribution Coronavirus COVID-19
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Alberta Ltd.
    • Isotechnika Pharma Inc.
    • Thunderbolt Pharma, Inc.
UsernamePublicRestriction

Register